American Journal of Clinical Dermatology

Papers
(The H4-Index of American Journal of Clinical Dermatology is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Alcohol and Smoking Cessation as Potential Modulators for Smoking-Associated Psoriasis Risk in Postmenopausal Women: The Women’s Health Initiative311
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review144
Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions120
Prognostic Biomarkers in Evolving Melanoma Immunotherapy106
The Current State of Systemic Therapy of Metastatic Uveal Melanoma90
Itch Relief and Quality-of-Life Improvement with Abrocitinib and Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE COMPARE and JADE DARE89
Disease Duration in Patients Recruited to Psoriasis Phase III Trials: A Systematic Review88
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials84
Performance of Staging Systems for Non-head and Neck Cutaneous Squamous Cell Carcinoma80
Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know79
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study77
Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments76
The Burden of Pediatric Psoriasis: A Systematic Review75
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study73
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks69
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review68
Agreement Between Nail Psoriasis Severity Index Scores by a Convolutional Neural Network and Dermatologists: A Retrospective Study at an Academic New York City Institution68
Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology65
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroi64
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?61
Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study57
Disease Modification in Psoriasis: Future Prospects for Long-Term Remission57
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation57
Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion57
Skin Cancer in Solid Organ Transplant Recipients: A Review57
48-Week Real-World Outcomes of Lebrikizumab Treatment for Atopic Dermatitis: Systemic Therapy-Naive Versus -Experienced Patients56
Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium56
Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry55
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment54
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management52
Ethnic Differences of Palmoplantar Pustulosis: A Systematic Review51
A Practice Approach to Acne Fulminans in Adolescents50
Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!49
Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment47
Dissecting Cellulitis of the Scalp: Current Insights and Therapeutic Advances46
Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives46
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis44
Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis43
Multiple Keratoacanthomas Associated with Genetic Syndromes: Narrative Review and Proposal of a Diagnostic Algorithm40
A Review of the Etiologies and Key Clinical Features of Secondary Hyperhidrosis40
0.13354587554932